Da Hee Han, PharmD

This was the first study to demonstrate the safety of peanut oral immunotherapy among preschool-aged children when administered as routine therapy in a hospital or clinic instead of a clinical trial setting.

The FDA has approved Keytruda as monotherapy for the first-line treatment of patients with stage III NSCLC.

The FDA issued a warning to Inova Genomics Laboratory for the illegal marketing of pharmacogenetic tests for predicting medication responses.

United Therapeutics has decided to discontinue the development of esuberaprost for the treatment of pulmonary arterial hypertension.

Circassia announced the FDA has approved Duaklir Pressair for the maintenance treatment of COPD.

Sandoz announced the launch of Treprostinil Injection, the first AP rated generic version of United Therapeutics’ Remodulin.

The FDA has approved Sunosi to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or OSA.

The FDA has accepted Priority Review Dupixent as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis.

The FDA has issued a warning letter to CanaRx for its involvement in the distribution of certain unapproved or misbranded drugs that may be harmful to US consumers.

In otherwise healthy patients, influenza treatment with baloxavir marboxil was found to be comparable, and on some efficacy measures, superior to neuraminidase inhibitors.

In otherwise healthy patients, influenza treatment with baloxavir marboxil was found to be comparable, and on some efficacy measures, superior to neuraminidase inhibitors.

In otherwise healthy patients, influenza treatment with baloxavir marboxil was found to be comparable, and on some efficacy measures, superior to neuraminidase inhibitors.